SHL Medical, a Swiss provider of self-injection solutions, announced on Thursday that it is planning to establish SHL Advantec, a sub-group dedicated to providing tooling and automation solutions to the healthcare sector and other industries.
SHL Advantec will be headquartered in Zug, Switzerland and will commence operations with more than 600 employees across its offices and production sites in Switzerland, China, Taiwan, Mexico and the United States.
SHL Medical's existing tooling and automation operations will be integrated into SHL Advantec, bringing its range of technologies, services and equipment portfolio to the new business. Together with SHL Medical's recent strategic acquisitions -- Swiss-based LCA Automation and SMC Mould Innovation and US-based Superior Tooling -- SHL Advantec will form a global operations network spanning three continents to deliver faster support and shorter supply chain services to SHL Advantec's diverse customer base. Leveraging its experience in medical devices and other industries, SHL Advantec says that it will focus on helping its customers advance production quality and resilience while continuing to support SHL Medical's growth in autoinjector manufacturing.
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US
HeartBeam secures FDA clearance for innovative at-home heart monitoring device
Eli Lilly to expand Wisconsin facility
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Abbott launches first patient procedures with investigational TAVI system
SHL Medical to establish tooling and automation sub-group
Epigenic Therapeutics receives New Zealand approval for EPI-003 clinical trial
GRAIL reports first patient tested with blood-based assay in TROPION-Lung12 Phase 3 study